What is the 13F Pro Quality Score for ZBH?

13F Pro ranks ZIMMER BIOMET HOLDINGS, INC. (ZBH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ZBH's current score at https://13fpro.ai/company/ZBH (free sign-up required for the full ranking).

Which hedge funds own the most ZBH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ZBH include DODGE & COX, BlackRock,, HARRIS ASSOCIATES L P. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ZBH as soon as new 13F filings post.

Where does 13F Pro source ZBH data?

All ZIMMER BIOMET HOLDINGS, INC. fundamentals and ownership data come directly from SEC EDGAR. ZIMMER BIOMET HOLDINGS, INC. files with the SEC under CIK 1136869. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ZBH in?

ZIMMER BIOMET HOLDINGS, INC. (ZBH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ZBH's revenue?

Per ZIMMER BIOMET HOLDINGS, INC.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Knees ($828.9M, +0.4% YoY); S.E.T. ($586.0M, +6.4% YoY); Hips ($562.7M, +5.0% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ZBH.

How often is ZBH research updated on 13F Pro?

ZBH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ZIMMER BIOMET HOLDINGS, INC.(ZBH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1136869 ZBH stock profile & AI dashboard →

13F Pro Quality Score

65.7/100

Rank #464 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

49.5/100

Profitability

59.0/100

Balance Sheet

62.5/100

Earnings Quality

85.3/100

Free Cash Flow

70.0/100

Institutional Flow

82.0/100

Revenue Scale

84.6/100

Dilution Risk

54.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ZBH Scores 66/100

exact factor attribution · 2026-09-11

ZBH's composite is driven by scale and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+5.2 pts

85th pct

Earnings quality

+3.5 pts

85th pct

Free cash flow

+3.0 pts

70th pct

Institutional flow

+1.6 pts

82th pct

Profitability

+1.4 pts

59th pct

Capital efficiency

+1.3 pts

63th pct

Shareholder dilution

+0.2 pts

55th pct

Revenue growth

-0.1 pts

50th pct

Earnings growth

-0.4 pts

42th pct

Latest change (2026-08-05): 65 → 63 · ↓ Earnings growth 41→32

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ZBH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ZIMMER BIOMET HOLDINGS, INC. (ZBH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZBH at 65.7/100 on a 32-signal composite quality model, placing it at rank #464 of 2,961 stocks — the top 25% of the AI-ranked universe. ZBH scores in the top quartile across earnings quality (85.3), revenue scale (84.6), institutional flow (82.0). Based on the latest XBRL financial filings (Q2 2026), ZIMMER BIOMET HOLDINGS, INC. reports quarterly revenue of $2.2B, net income of $198.3M, an operating margin of 15.0%. Top institutional holders of ZBH by reported 13-F value include DODGE & COX, BlackRock, HARRIS ASSOCIATES L P, based on the most recent SEC filings. ZBH trades on the NYSE exchange and files with the SEC under CIK 1136869. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZBH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ZIMMER BIOMET HOLDINGS, INC. directly from SEC EDGAR. ZIMMER BIOMET HOLDINGS, INC.'s 13F Pro composite quality score has ranged between 46 and 67 since 2021, currently 65.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about ZIMMER BIOMET HOLDINGS, INC.

Quirks, history, and lore behind ZBH — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · large-cap · listed on the NYSE · headquartered in a small Indiana city that calls itself the orthopedic capital of the world.
2
The Numbers
Annual revenue roughly $7–8 billion, with operations in over 25 countries and tens of thousands of employees — all in service of one very specific part of the human body.
3
The History
Its current form was born from a 2015 merger of two orthopedic giants — one founded in the 1920s in Indiana, the other a spinoff from a major medical conglomerate — creating a single dominant force in reconstructive joints.
4
The Secret
The company holds a commanding share of the global market for knee and hip replacement implants, meaning its handiwork is quietly installed in millions of aging knees worldwide.
5
The Lore
Warsaw, Indiana — population under 15,000 — is home to this company and several rivals, making it arguably the Silicon Valley of fake hips. The town basically runs on titanium and polyethylene.
6
The Giveaway
Two orthopedic titans — one named for a zimmer frame (well, sort of) and one named Biomet — merged their hip-and-knee empires and now hold a ZBH ticker on the NYSE.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ZBH's Business? Latest 10-Q Breakdown

✓ 35/35 datapoints verified

AI-extracted from ZIMMER BIOMET HOLDINGS, INC.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales grew 4.8% YoY to $2,177.0M with operating margin expanding to 15.0% from 14.4%, as Paragon 28 and strong ROSA Robot/bone cement sales drove diluted EPS up 34% to $1.03.

Biggest Revenue Drivers

Knees$828.9M+0.4% YoY

Benefited from opportunistic end-of-quarter customer purchases, market growth and new product introductions

S.E.T.$586.0M+6.4% YoY

Primarily the result of the Paragon 28 acquisition and growth in upper extremities and craniomaxillofacial/thoracic products

Biggest Revenue Drivers

Total revenue: $2,177.0M+4.8% YoY

Knees$828.9M+0.4% YoY

Benefited from opportunistic end-of-quarter customer purchases, market growth and new product introductions

S.E.T.$586.0M+6.4% YoY

Primarily the result of the Paragon 28 acquisition and growth in upper extremities and craniomaxillofacial/thoracic products

Hips$562.7M+5.0% YoY

Benefited from opportunistic end-of-quarter customer purchases, market growth and new product introductions

Technology & Data, Bone Cement and Surgical$199.4M+21.1% YoY

Primarily due to strong net sales of ROSA Robot and bone cement products

Largest Expense Items

Selling, general and administrative$899.3M+10.4% YoY

Higher variable/bonus selling expenses from increased net sales, Paragon 28-related expenses, higher litigation-related expense, higher bad debt charges and sales force investments

Cost of products sold (excl. intangible amortization)$635.5M+7.3% YoY

Higher sales volume, higher manufacturing costs, Paragon 28 inventory step-up to fair value, and net sales price declines, partly offset by favorable product mix

Intangible asset amortization$163.4M+1.7% YoY

Increased due to the Paragon 28 acquisition

Research and development$104.8M-7.5% YoY

Completion of initial EU Medical Device Regulation compliance spending, lower project spending and restructuring savings, partly offset by Paragon 28 and Monogram R&D

Margins: Operating profit margin rose to 15.0% of net sales from 14.4%, as lower R&D and acquisition/integration costs offset higher cost of products sold (29.2% vs 28.5%, from manufacturing costs and Paragon 28 inventory step-up) and higher SG&A (41.3% vs 39.2%).

Watch Items from the Filing

Displaced China distributors have formally and informally raised legal claims amid an ongoing overhaul of the go-to-market model there; the company cannot reasonably estimate losses beyond current accruals.
The Global Foot & Ankle reporting unit's estimated fair value exceeded its carrying value by only ~5%, a thin cushion since its assets stem almost entirely from the Paragon 28 acquisition.
Following a Supreme Court ruling invalidating IEEPA tariffs, the company expects to recover the full ~$77M it previously paid and already booked a ~$30M favorable cost-of-sales adjustment in H1 2026.
$1,201.5M of debt is now classified as current, including $571.5M of notes due December 2026 and $600.0M due February 2027.
Subsequent to quarter-end, the company signed agreements for new pain management and surgical technology with ~$245M initial cash consideration plus up to $210M in contingent milestone payments.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$2.2B

Net Income

Q2 2026

$198.3M

Free Cash Flow

Q2 2026

$393.6M

Operating Margin

Q2 2026

15.0%

ROIC

Q2 2026

6.5%

D/E Ratio

Q2 2026

0.59

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+7.2% YoY

$8.23BFY 2025

FY22 $6.94BFY23 $7.39BFY24 $7.68BFY25 $8.23B

Net Income

-22.0% YoY

$705.1MFY 2025

FY22 $231.4MFY23 $1.02BFY24 $903.8MFY25 $705.1M

Operating Income

-14.6% YoY

$1.10BFY 2025

FY22 $696.3MFY23 $1.28BFY24 $1.29BFY25 $1.10B

EPS (Diluted)

-19.9% YoY

$3.55FY 2025

FY22 $1.10FY23 $4.88FY24 $4.43FY25 $3.55

Total Assets

+8.1% YoY

$23.09BFY 2025

FY22 $21.07BFY23 $21.50BFY24 $21.37BFY25 $23.09B

Total Debt

+21.2% YoY

$7.52BFY 2025

FY22 $5.70BFY23 $5.80BFY24 $6.20BFY25 $7.52B

Op. Cash Flow

+13.2% YoY

$1.70BFY 2025

FY22 —FY23 $1.58BFY24 $1.50BFY25 $1.70B

Free Cash Flow

+13.7% YoY

$1.47BFY 2025

FY22 —FY23 $1.29BFY24 $1.30BFY25 $1.47B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$8.23B +7.2%	$7.68B +3.8%	$7.39B +6.5%	$6.94B +1.6%	$6.83B +11.4%	$6.13B
Net Income	$705.1M -22.0%	$903.8M -11.7%	$1.02B +342.5%	$231.4M -42.4%	$401.6M +389.1%	$-138.9M
Operating Income	$1.10B -14.6%	$1.29B +0.6%	$1.28B +83.5%	$696.3M -19.1%	$860.3M +935.3%	$83.1M
EPS (Diluted)	$3.55 -19.9%	$4.43 -9.2%	$4.88 +343.6%	$1.10 -42.4%	$1.91 +385.1%	$-0.67
Total Assets	$23.09B +8.1%	$21.37B -0.6%	$21.50B +2.0%	$21.07B -10.2%	$23.46B -3.9%	$24.42B
Total Debt	$7.52B +21.2%	$6.20B +7.0%	$5.80B +1.8%	$5.70B -19.7%	$7.10B -12.3%	$8.10B
Operating Cash Flow	$1.70B +13.2%	$1.50B -5.2%	$1.58B	—	$1.50B +24.5%	$1.20B
Free Cash Flow	$1.47B +13.7%	$1.30B +0.4%	$1.29B	—	$1.36B +24.1%	$1.09B

Get alerted when ZBH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ZIMMER BIOMET HOLDINGS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ZBH

DODGE & COX
$2.1B24,124,735 sh
BlackRock, Inc.
$1.3B15,614,847 sh
HARRIS ASSOCIATES L P
$1.1B12,738,025 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.1B12,634,937 sh
Capital International Investors
$1.0B12,183,614 sh
STATE STREET CORP
$766.3M8,877,171 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$726.7M8,441,747 sh
GEODE CAPITAL MANAGEMENT, LLC
$458.7M5,349,223 sh
PRICE T ROWE ASSOCIATES INC /MD/
$413.0M4,797,157 sh
Invesco Ltd.
$342.6M3,979,860 sh

Fund	Value	Shares
DODGE & COX	$2.1B	24,124,735
BlackRock, Inc.	$1.3B	15,614,847
HARRIS ASSOCIATES L P	$1.1B	12,738,025
VANGUARD CAPITAL MANAGEMENT LLC	$1.1B	12,634,937
Capital International Investors	$1.0B	12,183,614
STATE STREET CORP	$766.3M	8,877,171
VANGUARD PORTFOLIO MANAGEMENT LLC	$726.7M	8,441,747
GEODE CAPITAL MANAGEMENT, LLC	$458.7M	5,349,223
PRICE T ROWE ASSOCIATES INC /MD/	$413.0M	4,797,157
Invesco Ltd.	$342.6M	3,979,860

Companies Similar to ZBH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BDX

BECTON DICKINSON & CO

AI score

Very similar · 30 shared holders

HARRIS ASSOCIATES L P Boston Trust Walden Corp Meridiem Capital Partners LP

IQV

IQVIA HOLDINGS INC.

AI score

Very similar · 23 shared holders

HARRIS ASSOCIATES L P Boston Partners THOMPSON SIEGEL & WALMSLEY LLC

PFE

PFIZER INC

AI score

Very similar · 35 shared holders

SOUND SHORE MANAGEMENT INC /CT/CAUSEWAY CAPITAL MANAGEMENT LLC WILSEY ASSET MANAGEMENT INC

GEHC

GE HealthCare Technologies Inc.

AI score

Very similar · 42 shared holders

DODGE & COX HARRIS ASSOCIATES L P HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 31 shared holders

Capital International Investors PRIMECAP MANAGEMENT CO/CA/Vestal Point Capital, LP

BIIB

BIOGEN INC.

AI score

Very similar · 32 shared holders

PRIMECAP MANAGEMENT CO/CA/Boston Partners CAUSEWAY CAPITAL MANAGEMENT LLC

MDT

Medtronic plc

AI score

Very similar · 31 shared holders

DODGE & COX HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC EQUITY INVESTMENT CORP

ABT

ABBOTT LABORATORIES

AI score

Very similar · 28 shared holders

Capital International Investors Vestal Point Capital, LP Holocene Advisors, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ZBH on your watchlist

Track score changes the day ZIMMER BIOMET HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ZBH a good stock to buy?

13F Pro's AI-powered analysis of ZIMMER BIOMET HOLDINGS, INC. (ZBH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZBH are available on the ZBH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZBH is classified as a large company.

Which hedge funds own ZBH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZBH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ZIMMER BIOMET HOLDINGS, INC.'s investment landscape.